Liu Yi, Song Lijie, Ma Doudou, Lv Fang, Xu Xiaojie, Wang Jianyi, Xia Weibo, Jiang Yan, Wang Ou, Song Yuwen, Xing Xiaoping, Li Mei
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
BGI Shenzhen: Binhai Genomics Institute, BGI-Tianjin, BGI-Shenzhen, Tianjin 300308, China; Tianjin Translational Genomics Center, BGI-Tianjin, Tianjin 300308, China.
Clin Chim Acta. 2016 Oct 1;461:172-80. doi: 10.1016/j.cca.2016.07.012. Epub 2016 Jul 20.
Osteogenesis imperfecta (OI) is a rare inherited disease characterized by increased bone fragility and vulnerability to fractures. Recently, WNT1 is identified as a new candidate gene for OI, here we detect pathogenic mutations in WNT1 and analyze the genotype-phenotype association in four Chinese families with OI.
We designed a targeted next generation sequencing panel with known fourteen OI-related genes. We applied the approach to detect pathogenic mutations in OI patients and confirmed the mutations with Sanger sequencing and cosegregation analysis. Clinical fractures, bone mineral density (BMD) and the other clinical manifestations were evaluated. We also observed the effects of bisphosphonates in OI patients with WNT1 mutations.
Four compound heterozygous mutations (c.110T>C; c.505 G>T; c. 385G>A; c.506 G>A) in WNT1 were detected in three unrelated families. These four mutations had not been reported yet. A recurrent homozygous mutation (c.506dupG) was identified in the other two families. These patients had moderate to severe OI, white to blue sclera, absence of dentinogenesis imperfecta and no brain malformation. We did not observe clear genotype-phenotype correlation in WNT1 mutated OI patients. Though bisphosphonates increased BMD in WNT1 related OI patients, height did not increase and fracture continued.
We reported four novel heterozygous variants and confirmed a previous reported WNT1 mutation in four Chinese families with a clinical diagnosis of OI. Our study expanded OI spectrum and confirmed moderate to severe bone fragility induced by WNT1 defects.
成骨不全症(OI)是一种罕见的遗传性疾病,其特征为骨脆性增加和易骨折。最近,WNT1被鉴定为OI的一个新候选基因,在此我们检测WNT1中的致病突变,并分析4个中国成骨不全症家庭的基因型-表型关联。
我们设计了一个针对已知14个与OI相关基因的靶向二代测序panel。我们应用该方法检测OI患者中的致病突变,并用桑格测序和共分离分析确认突变。评估临床骨折、骨密度(BMD)和其他临床表现。我们还观察了双膦酸盐对携带WNT1突变的OI患者的影响。
在3个无关家庭中检测到WNT1的4个复合杂合突变(c.110T>C;c.505 G>T;c. 385G>A;c.506 G>A)。这4个突变尚未见报道。在另外两个家庭中鉴定出一个复发性纯合突变(c.506dupG)。这些患者患有中度至重度OI,巩膜呈白色至蓝色,无牙本质发育不全,无脑畸形。我们在携带WNT1突变的OI患者中未观察到明确的基因型-表型相关性。尽管双膦酸盐增加了与WNT1相关的OI患者的骨密度,但身高未增加,骨折仍继续发生。
我们报道了4个新的杂合变异,并在4个临床诊断为OI的中国家庭中证实了先前报道的WNT1突变。我们的研究扩展了OI的疾病谱,并证实了WNT1缺陷引起的中度至重度骨脆性。